PHASE I/II TRIAL TETRATHIOMOLYBDATE (TM) IN PTS W/ USUAL INTERSTITIAL PNEUMONIA

I/II 期试验四硫代钼酸盐 (TM) 在患有普通间质性肺炎的 PTS 中的应用

基本信息

  • 批准号:
    7376529
  • 负责人:
  • 金额:
    $ 2.55万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2006
  • 资助国家:
    美国
  • 起止时间:
    2006-04-05 至 2007-02-28
  • 项目状态:
    已结题

项目摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Usual interstitial pneumonia (UIP) is a type of pulmonary fibrosis that is associated with scarring of the lung and is often fatal. The average survival is 2-4 years from the time of diagnosis. Angiogenesis, the ability to grow new blood vessels, is believed to be a key component required for the fibrotic response typical of UIP. Tetrathiomolybdate (TM) is an anticopper drug developed for the treatment of Wilson's disease (a copper disorder that affects the liver). TM also produces an antiangiogenic effect in non-Wilson's disease patients with cancer, and in animal tumor models, by lowering systemic copper levels. The rationale for a trial of TM in UIP stems from its successful use in the bleomycin mouse model of pulmonary fibrosis, and its antifibrotic, antiinflammatory, antiangiogenic properties. This open-label study for patients with UIP that have failed previous treatment will follow patients for one year at three-month intervals. At each of the visits pulmonary function studies and quality of life questionnaires will be performed. A high resolution CT scan (a type of x-ray) and a six minute walk test will be performed at baseline as well as after 12 months of therapy. TM will be given orally and the dose will be titrated to inhibit angiogenesis without causing toxicity from copper deficiency. Patients will be monitored weekly initially and then biweekly and monthly if appropriate. The primary endpoint is change in pulmonary function after 12 months of therapy. Research records will be kept in a password protected database accessible only by study investigators. Written documents will be kept in patient binders in a locked study office. Patients will give written informed consent to participate in this study.
该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者(PI)可能从另一个NIH来源获得主要资金,因此可以在其他CRISP条目中表示。所列机构为中心,不一定是研究者所在机构。肺间质性肺炎(UIP)是一种与肺瘢痕形成相关的肺纤维化,通常是致命的。从诊断开始,平均生存期为2-4年。血管生成,即生长新血管的能力,被认为是UIP典型的纤维化反应所需的关键组成部分。四硫代钼酸盐(TM)是一种抗铜药物,用于治疗威尔逊病(一种影响肝脏的铜紊乱)。TM还通过降低全身铜水平,在患有癌症的非威尔逊病患者和动物肿瘤模型中产生抗血管生成作用。在UIP中进行TM试验的基本原理源于其在肺纤维化的博来霉素小鼠模型中的成功使用,以及其抗纤维化、抗血管生成的特性。这项针对既往治疗失败的UIP患者的开放标签研究将以3个月的间隔对患者进行为期一年的随访。每次访视时,将进行肺功能研究和生活质量问卷调查。将在基线和治疗12个月后进行高分辨率CT扫描(一种X射线)和6分钟步行试验。TM将口服给药,剂量将滴定,以抑制血管生成,而不会引起铜缺乏症的毒性。最初每周监测一次患者,然后每两周和每月(如适用)监测一次。主要终点是治疗12个月后肺功能的变化。研究记录将保存在密码保护的数据库中,仅研究者可访问。书面文件将保存在上锁的研究办公室的患者文件夹中。患者将提供参与本研究的书面知情同意书。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

KEVIN R FLAHERTY其他文献

RACE-SPECIFIC REFERENCE VALUES IMPEDE ACCESS TO CARE FOR BLACK AND HISPANIC PATIENTS WITH PULMONARY FIBROSIS
  • DOI:
    10.1016/j.chest.2023.07.2040
  • 发表时间:
    2023-10-01
  • 期刊:
  • 影响因子:
  • 作者:
    AYODEJI ADEGUNSOYE;WENDI R MASON BACHMAN;KEVIN R FLAHERTY;ZHONGZE LI;SACHIN GUPTA
  • 通讯作者:
    SACHIN GUPTA
ASSOCIATIONS OF PLASMA OMEGA-3 FATTY ACIDS WITH PROGRESSION AND SURVIVAL IN PULMONARY FIBROSIS
  • DOI:
    10.1016/j.chest.2023.07.1998
  • 发表时间:
    2023-10-01
  • 期刊:
  • 影响因子:
  • 作者:
    JOHN KIM;SHWU-FAN MA;JENNIE MA;YONG HUANG;CATHERINE BONHAM;JUSTIN OLDHAM;AYODEJI ADEGUNSOYE;MARY E STREK;KEVIN R FLAHERTY;EMMA STRICKLAND;JOSHUA J MOONEY;SHRESTHA GHOSH;LAURIE GLIMCHER;KRISHNA RAO MADDIPATI;IMRE NOTH
  • 通讯作者:
    IMRE NOTH

KEVIN R FLAHERTY的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('KEVIN R FLAHERTY', 18)}}的其他基金

Prospective tReatment EffiCacy in IPF uSlng genOtype for Nac Selection (PRECISIONS) trial and Molecular Endophenotyping in Idiopathic Pulmonary Fibrosis and Interstitial Lung Diseases study
IPF 使用基因型进行 Nac 选择 (PRECISIONS) 试验和特发性肺纤维化和间质性肺疾病分子内表型研究的前瞻性治疗效果
  • 批准号:
    10596595
  • 财政年份:
    2019
  • 资助金额:
    $ 2.55万
  • 项目类别:
Prospective tReatment EffiCacy in IPF uSlng genOtype for Nac Selection (PRECISIONS) trial and Molecular Endophenotyping in Idiopathic Pulmonary Fibrosis and Interstitial Lung Diseases study
IPF 使用基因型进行 Nac 选择 (PRECISIONS) 试验和特发性肺纤维化和间质性肺疾病分子内表型研究的前瞻性治疗效果
  • 批准号:
    10385682
  • 财政年份:
    2019
  • 资助金额:
    $ 2.55万
  • 项目类别:
Prospective tReatment EffiCacy in IPF uSlng genOtype for Nac Selection (PRECISIONS) trial and Molecular Endophenotyping in Idiopathic Pulmonary Fibrosis and Interstitial Lung Diseases study
IPF 使用基因型进行 Nac 选择 (PRECISIONS) 试验和特发性肺纤维化和间质性肺疾病分子内表型研究的前瞻性治疗效果
  • 批准号:
    10021690
  • 财政年份:
    2019
  • 资助金额:
    $ 2.55万
  • 项目类别:
Forging a road to personalized medicine in interstitial lung diseases
开辟间质性肺疾病个体化医疗之路
  • 批准号:
    8656765
  • 财政年份:
    2012
  • 资助金额:
    $ 2.55万
  • 项目类别:
Forging a road to personalized medicine in interstitial lung diseases
开辟间质性肺疾病个体化医疗之路
  • 批准号:
    8462680
  • 财政年份:
    2012
  • 资助金额:
    $ 2.55万
  • 项目类别:
Forging a road to personalized medicine in interstitial lung diseases
开辟间质性肺疾病个体化医疗之路
  • 批准号:
    8224611
  • 财政年份:
    2012
  • 资助金额:
    $ 2.55万
  • 项目类别:
Forging a road to personalized medicine in interstitial lung diseases
开辟间质性肺疾病个体化医疗之路
  • 批准号:
    9187992
  • 财政年份:
    2012
  • 资助金额:
    $ 2.55万
  • 项目类别:
CTRIP: Molecular phenotypes of rapidly progressive idiopathic pulmonary fibrosis
CTRIP:快速进展性特发性肺纤维化的分子表型
  • 批准号:
    7939866
  • 财政年份:
    2009
  • 资助金额:
    $ 2.55万
  • 项目类别:
CTRIP: Molecular phenotypes of rapidly progressive idiopathic pulmonary fibrosis
CTRIP:快速进展性特发性肺纤维化的分子表型
  • 批准号:
    7857151
  • 财政年份:
    2009
  • 资助金额:
    $ 2.55万
  • 项目类别:
Longitudinal, computer assisted analysis in IPF
IPF 的纵向计算机辅助分析
  • 批准号:
    8117529
  • 财政年份:
    2008
  • 资助金额:
    $ 2.55万
  • 项目类别:

相似海外基金

Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
  • 批准号:
    10752129
  • 财政年份:
    2024
  • 资助金额:
    $ 2.55万
  • 项目类别:
Preclinical Development of a Novel Therapeutic Agent for Idiopathic Pulmonary Fibrosis
特发性肺纤维化新型治疗剂的临床前开发
  • 批准号:
    10696538
  • 财政年份:
    2023
  • 资助金额:
    $ 2.55万
  • 项目类别:
CD38 modulation of NAD metabolism driving scleroderma pathogenesis
CD38 调节 NAD 代谢驱动硬皮病发病机制
  • 批准号:
    10733929
  • 财政年份:
    2023
  • 资助金额:
    $ 2.55万
  • 项目类别:
Mechanistic studies of the genetic contribution of desmoplakin to pulmonary fibrosis in alveolar type 2 cells
桥粒斑蛋白对肺泡2型细胞肺纤维化的遗传贡献机制研究
  • 批准号:
    10736228
  • 财政年份:
    2023
  • 资助金额:
    $ 2.55万
  • 项目类别:
Mechanisms Regulating Lung Injury and Early Lung Fibrosis
肺损伤和早期肺纤维化的调节机制
  • 批准号:
    10627593
  • 财政年份:
    2023
  • 资助金额:
    $ 2.55万
  • 项目类别:
Interferon Regulatory Factor 7 Links Interferon Pathway Activation to the Exaggerates Fibrotic Response in Systemic Sclerosis
干扰素调节因子 7 将干扰素通路激活与系统性硬化症中过度的纤维化反应联系起来
  • 批准号:
    10682192
  • 财政年份:
    2023
  • 资助金额:
    $ 2.55万
  • 项目类别:
New mechanism-based TREM-1 therapy for acute respiratory distress syndrome
基于新机制的 TREM-1 疗法治疗急性呼吸窘迫综合征
  • 批准号:
    10678788
  • 财政年份:
    2023
  • 资助金额:
    $ 2.55万
  • 项目类别:
Development of a targeted TGF-b therapeutic that selectively blocks lung fibrosis in idiopathic pulmonary fibrosis (IPF) patients
开发选择性阻断特发性肺纤维化 (IPF) 患者肺纤维化的靶向 TGF-b 疗法
  • 批准号:
    10697961
  • 财政年份:
    2023
  • 资助金额:
    $ 2.55万
  • 项目类别:
Delineating the role of let-7 microRNA on lung AT2 cell homeostasis, alveolar regeneration, and interstitial lung disease
描述let-7 microRNA对肺AT2细胞稳态、肺泡再生和间质性肺疾病的作用
  • 批准号:
    10634881
  • 财政年份:
    2023
  • 资助金额:
    $ 2.55万
  • 项目类别:
Mechanosensor Function in the Control of Gas Exchange Surface Size and Composition
机械传感器在控制气体交换表面尺寸和成分中的功能
  • 批准号:
    10720855
  • 财政年份:
    2023
  • 资助金额:
    $ 2.55万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了